Balyasny Asset Management
IMRX icon

Balyasny Asset Management’s Immuneering IMRX Stock Holding History

Balyasny Asset Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,366
Closed -$163K – 2987
2022
Q3 		$163K Buy
+11,366
New +$90.3K ﹤0.01% 2343

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Balyasny Asset Management's IMRX Position: Q4 2022 in Review

Balyasny Asset Management sold out of Immuneering (IMRX) in Q4 2022, closing a stake of 11,366 shares — an estimated $163K sold.

Balyasny Asset Management first reported a position in IMRX in Q3 2022 and held it in 1 quarter. The position peaked at $163K in Q3 2022. 34 funds tracked by Wall St. Rank hold IMRX as of Q4 2022.

  • Balyasny Asset Management reported no remaining Immuneering position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 11,366 Immuneering shares in Q4 2022, an estimated $163K.
  • Balyasny Asset Management first reported a position in Immuneering in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Immuneering position peaked at $163K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held Immuneering as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.